GLAXOSMITHKLINE AND ADOLOR ANNOUNCE THE COMPLETION OF ENROLLMENT OF PIVOTAL CLINICAL STUDIES OF ENTEREG
GlaxoSmithKline and Adolor Corporation announced today that GSK has completed
enrollment of the Phase 3 clinical program to evaluate the efficacy and safety
of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal
adverse events caused by opioids used for persistent non-cancer pain.
Genetic Engineering News